Conor Hale
Showing 1–2 of 2 transcripts.
- Milken Institute1h 1m
Decoding Disease: Can Genetics Unlock New Interventions? | Future of Health Summit 2024
Conor Hale, Colleen Campbell, Lon Cardon, Bernard Kwabi-Addo, Benjamin Neale
Experts highlight that while genomic knowledge has expanded to 12,000 identified variants, translating these discoveries into clinical care remains hindered by insurance barriers, provider literacy gaps, and biased data representation. To overcome these bottlenecks, the field is increasingly leveraging artificial intelligence for tumor heterogeneity analysis and shifting toward deconstructing common diseases into rare, monogenic subsets for targeted therapies. With sequencing costs dropping to roughly $200, stakeholders anticipate widespread population screening programs and systematic variant analysis across human diseases becoming feasible within the next decade.
- Milken Institute1h 1m
What's Trending in MedTech? | Milken Institute Global Conference 2024
Conor Hale, Kelvin Baggett, Andrew Fish, Nada Hanafi, Ryan Lakin, Michelle Tarver
Facing a constrained 2023 investment climate, the industry is pivoting from speculative hype to value-driven innovations in women's health, AI, and genomic technologies that prioritize clear patient outcomes. Regulatory frameworks like the FDA's TAP and new real-world evidence protocols are accelerating approvals while shifting focus toward patient-integrated design and equitable access. Leaders such as Abbott and J&J are now embedding affordability and diversity into R&D, ensuring devices function as intuitive, home-based solutions that address systemic provider shortages and health inequities.